Sorafenib in advanced clear-cell renal-cell carcinoma

New England Journal of Medicine

Volumn 356, Issue 2, 2007, Pages 125-134

  Escudier, Bernard ^a   Eisen, Tim ^b   Stadler, Walter M ^c   Szczylik, Cezary ^d   Oudard, Stéphane ^e   Siebels, Michael ^f   Negrier, Sylvie ^g   Chevreau, Christine ^h   Solska, Ewa ⁱ   Desai, Apurva A ^c   Rolland, Frédéric ^j   Demkow, Tomasz ^k   Hutson, Thomas E ^l   Gore, Martin ^m   Freeman, Scott ⁿ   Schwartz, Brian ^o   Shan, Minghua ^o   Simantov, Ronit ^o   Bukowski, Ronald M ^p  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Cambridge Research Institute   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

^d MILITARY INSTITUTE OF MEDICINE   (Poland)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g CENTRE LÉON BÉRARD   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ Wojewodzka Przychodnia Onkolog   (Poland)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^m ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁿ ONYX PHARMACEUTICALS   (United States)

^o BAYER CORPORATION   (United States)

^p TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERFERON; INTERLEUKIN 2; PLACEBO; SORAFENIB;

ADULT; AGED; ALOPECIA; ANEMIA; ANGIOGENESIS; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 33846148701     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa060655     Document Type: Article

References (22)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
3. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
4. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-7.
5. Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000;6:Suppl 1:S93-S98.
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
8. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34.
9. Chang YS, Henderson A, Xue D, et al. BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Proc Am Assoc Cancer Res 2005;46. abstract.
10. Levy J, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc Am Assoc Cancer Res 2006;47:213-4. abstract.
11. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
12. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
13. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90.
14. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005;23:LBA4511. abstract.
15. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11.
16. Escudier B, Venner P, Stern P, et al. Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: lessons from a large phase III trial. J Clin Oncol 2004;22:14S. abstract.
17. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-5.
18. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 1999;17:2039-43.
19. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
20. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
21. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005;23:380s. abstract.
22. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and